You are here: Industry Insights > NMPA

News List

InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA PharmaSources.com
September 06, 2022
So far, no BTK inhibitor has ever been approved for treating patients with R/R MZL in China, and hope that orelabrutinib can fill the gap in this therapeutic area.
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström’s Macroglobulinemia in China March 14, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced recently...
China increases accessibility to rare disease treatment NMPA/Xinhua
December 24, 2021
Two-and-half-year-old Xuanxuan survived a rare kidney disease in early December, thanks to fast-track approval of the transplant.
NMPA Deputy Commissioner participates in ICMRA’s 2021 online summit NMPA
December 06, 2021
Other participants included related officials from the NMPA's Department of Science, Technology and International Cooperation, Department of Drug Registration, Department of Drug Regulation...
Meeting on drug, medical device, cosmetic regulation in China held during 4th CIIE NMPA
November 11, 2021
A meeting on the regulation of drugs, medical devices and cosmetics in China was held on Nov 6 in Shanghai during the fourth China International Import Expo (CIIE).
NMPA releases 2nd group of key projects for China’s drug regulatory science action plan October 25, 2021
The National Medical Products Administration (NMPA) issued a list of the second group of key projects for China's drug regulatory science action plan based on the summary of the implementation of the first group on June 24.
Seminar held to boost drug regulatory cooperation between BRI countries NMPA
September 23, 2021
Co-sponsored by China's National Medical Products Administration (NMPA) and Ministry of Commerce, the Seminar on Drug Regulation and Development Cooperation for Belt and Road Countries...
6th China-ASEAN Summit for Drug Development and Cooperation opens in Guangxi NMPA
September 22, 2021
Co-sponsored by China's National Medical Products Administration (NMPA) and the government of the Guangxi Zhuang autonomous region, the Sixth China-ASEAN Summit...
Hua Medicine Announces 2020 Interim Results ACN Newswire
September 09, 2021
New Drug Application for a potential First in Class GKA dorzagliatin accepted by NMPA Expansion of indications for dorzagliatin strengthened R&D pipeline
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China prnasia
August 11, 2021
InnoCare Pharma, a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) for starting ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page